- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00527475
Ranibizumab and Reduced Fluence PDT for AMD (RAP)
June 5, 2013 updated by: Texas Retina Associates
Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration.
However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage.
The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomized, prospective, multicenter trial will compare two groups of patients with subfoveal choroidal neovascularization secondary to AMD.
One group will receive 0.5 mg.
ranibizumab intraocularly initially.
This will be repeated monthly for 3 months total and then as needed over the period of one year.
The other group will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day.
The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
Re-treatment will be determined by the individual investigator based on visual acuity, retinal thickness as measured by optical coherence tomography (OCT), and fluorescein angiography.
Visual acuity and OCT measurements will be performed by masked examiners.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93103
- California Retina Consultants & Research Foundation
-
-
Michigan
-
Ann Arbor, Michigan, United States, 49301
- Associated Retinal Consultants
-
-
Texas
-
Arlington, Texas, United States, 76012
- Texas Retina Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willingness to sign informed consent.
- Age greater than 50.
- Evidence of macular degeneration in the form of drusen in either eye.
- Visual acuity of 20/25 to 20/800.
Subfoveal choroidal neovascularization. Both occult and classic subtypes will be allowed. If lesion is purely occult there has to be one of the following:
- Recent loss of vision (5 letters on ETDRS or doubling of visual angle by snellen)
- Documented enlargement of lesion on FA
- Increase of 50 microns or more in the central subfield on OCT
- New blood
- Total active lesion must be less than 12 disc areas in size. -
Exclusion Criteria:
- Myopia, ocular histoplasmosis, or other retinal pathology that could affect vision
- Previous treatment of the enrolled eye for CNV
- Intraocular surgery within 6 weeks of enrollment
- Geographic atrophy, subretinal fibrosis, or pigment epithelial tear involving the fovea of the eligible eye
- Known hypersensitivity to verteporfin
- Medical condition that would preclude regular follow-up for one year.
- Previous vitrectomy
- Media opacities limiting visual acuity, retinal examination, or retinal imaging.
- A lesion where > 50% of the lesion is a pigment epithelial detachment. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group I
Group I will receive 0.5 mg.
ranibizumab intraocularly initially.
This will be repeated monthly for 3 months total and then as needed over the period of one year.
|
0.5 mg.
given as an intraocular injection
|
Experimental: Group II
Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day.
The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
|
0.5 mg.
given as an intraocular injection
Standard dosage of 6 mgs.
/ meter2 of body surface area given intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Number of Days to Retreatment. The Total Number of Treatments Given Over One Year. The Percentage of Patients With More Than a 15 Letter Increase in Vision at 12 Months. The Mean Change in Macular Volume as Measured by OCT at 3, 6, and 12 Months.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: David Callanan, MD, Texas Retina Associates
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
September 9, 2007
First Submitted That Met QC Criteria
September 9, 2007
First Posted (Estimate)
September 11, 2007
Study Record Updates
Last Update Posted (Estimate)
June 7, 2013
Last Update Submitted That Met QC Criteria
June 5, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAP AMD Trial
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted